Perspective · 30 Dec 2025
Conference abstractPublished 26 Nov 2018
Recombinant cyclins and their CDKs in Escherichia coli: expression and purification for soluble active products and characterization with putative inhibitors
University of Thessaly, Greece; American College of Thessaloniki, Greece
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Targeting cyclins enables us to interfere with cell cycle in order to inhibit the cancerous process which is the result of a nonprober regulation of this cell cycle control. Through cell cycle, cyclin dependent kinases (CDKs) as well as their activation partners, cyclins, are regulators of progression and proliferation through activation of cell cycle checkpoints and inhibited by cyclin-dependent kinase inhibitors (CKIs), thus they have been widely held as anti-cancer targets. Existing synthesized peptides, designed with REPLACE (REplacement with Partial Ligand Alternatives through Computational Enrichment). This structure-activity co-relation with non-fluorescent peptides as cyclin groove putative inhibitors (CGI) where tested. Although, the path from expression to high levels of yield and purity, as well as from purified protein solution to well-diffracting crystal is rarely a straightforward highway. Moreover an overexpressed or purified protein is either unfolded or misfolded leading to uncertain results. Furthermore protein stability such as salt concentration precipitates the product. So a number of parameters are taking place to find promising lead conditions. Seeking targets for drug development, tumor suppression, anti-cancer targets or other inhibition, more and more screening and optimization is needed and required different strategies while struggling with insoluble aggregates (inclusion bodies formation) and the stability of the protein of each step of the process. So how do we compete with these challenges? To answer these emerging questions, the lecture will give a glimpse on ours experience working on proteins with very low expression in appropriate bacterial vectors, in E. coli, as one of the most widely used expression hosts. Recent Publications: 1. Andrews M J I, Kontopidis G, McInnes et al. (2006) REPLACE: A strategy for iterative design of cyclin-binding groove inhibitors. ChemBioChem 7(12):1909â??1915. 2. C Papaneophytou and G Kontopidis (2016) A comparison of statistical approaches used for the optimization of soluble protein expression in Escherichia coli. Protein Expression and Purification 120:126-37. 3. Qing-di Cheng et al. (2017) Effect of the weather conditions during solution preparation on lysozyme crystallization. J. Appl. Cryst. 50:1341-1351. 4. Chou C P (2007) Engineering cell physiology to enhance recombinant protein production in Escherichia coli. Appl Microbiol Biotechnol 76(3):521â??532. 5. Kyratsous C A, Silverstein S J, DeLong C R and Panagiotidis C A (2009) Chaperone-fusion expression plasmid vectors for improved solubility of recombinant proteins in Escherichia coli. Gene 440(1â??2):9â??15.
Subjects
Biochemistry & BiotechnologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Longdom does not store it.
More from this journal
The newest in Journal of Proteomics & Bioinformatics.
Commentary · 30 Dec 2025
Machine Learning in Bioinformatics Transforming Biological Data into Predictive Insights
Perspective · 30 Dec 2025
Post-Translational Modifications as Dynamic Regulators of Proteome Complexity and Cellular Function
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Proteomics & Bioinformatics
- SubjectBiochemistry & Biotechnology
- BylineArticles whose byline prints “Nikolopoulos Vaios”
- BylineArticles whose byline prints “Grigoroudis Asterios”
- BylineArticles whose byline prints “Kontopidis George”
